Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation [letter]

Oettle, Helmut; Wilborn, Freimut; Ca, Schmidt; Siegert, W.

doi:10.1182/blood.v82.7.2257.bloodjournal8272257

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we found the IVIGs to contain very high titres of anti‐EBV antibodies. Indeed, IVIG has been previously used, in addition to antiviral therapy and alpha interferon, to successfully treat post‐transplantation EBV‐induced lymphadenopathy, lymphoproliferative syndrome or hepatitis (Oettle et al ., 1993; Taguchi et al ., 1994). In contrast, our results for anti‐CMV antibodies were negative in all IVIG batches.…”

Section: Discussionmentioning

confidence: 99%

In vitroantiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases*

Krause

Sherer

et al. 2002

Transfusion Medicine

112

View full text Add to dashboard Cite

The identification of specific antimicrobial activity of intravenous immunoglobulin (IVIG) preparations against particular microbial pathogens can assist in determining their therapeutic potential for specific infectious diseases. We analysed five different commercial IVIG preparations for the presence of antibodies directed against a large panel of viral, bacterial, fungal and parasitic pathogens. All IVIG batches contained high activity against herpesviruses types 1, 2, 6 and 7, as well as against varicella zoster virus, Epstein-Barr virus (EBV), measles, mumps, rubella and parvovirus B19. Some IVIG batches also had a significant activity against adenovirus and Saint Louis encephalitis virus. The IVIGs held high activity against several bacterial pathogens, including Mycoplasma pneumonia, Chlamydia pneumonia, Helicobacter pylori and tetanus. No activity was found against various parasitic and fungal pathogens. Our findings may provide further support for the use of IVIG for the prevention and treatment of infections caused by specific viral and bacterial pathogens.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitroantiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases*

Krause

Sherer

et al. 2002

Transfusion Medicine

112

View full text Add to dashboard Cite

show abstract

“…Epstein-Barr virus (EBV) antibodies are present in variable titers in IVIG, particularly in CMVIG, because donors with high titers of CMV often have high titers of EBV. A few patients with posttransplant EBV-induced lymphoproliferative syndrome or hepatitis have been treated successfully with a combination of IGIV or CMVIG, antiviral therapy and interferon-a [72][73][74]. Similar results have been achieved in EBV infection in X-linked lymphoproliferative syndrome: such patients have a hereditary predisposition to overwhelming EBV infection [75].…”

Section: Epstein-barr Virus Infectionmentioning

confidence: 94%

Therapeutic Use of Immunoglobulins

Stiehm

Ballow

Lehman

2010

Advances in Pediatrics

View full text Add to dashboard Cite

“…Feranchak et al (47) successfully treated a patient with fulminant EBV hepatitis by liver transplantation, antiviral therapy, and EBV antibody (using CMVIG, which contains high titers of anti-EBV antibodies). CMVIG or IVIG (containing anti-EBV antibodies) has been used, in addition to antiviral therapy and alpha interferon, to successfully treat posttransplantation EBV-induced lymphadenopathy, lymphoproliferative syndrome, or hepatitis (42,126,171). However, IVIG and alpha interferon were not successful in a patient with X-linked lymphoproliferative syndrome (129).…”

Section: Herpesvirus Infectionsmentioning

confidence: 99%

Passive Immunity in Prevention and Treatment of Infectious Diseases

2000

View full text Add to dashboard Cite

SUMMARY Antibodies have been used for over a century in the prevention and treatment of infectious disease. They are used most commonly for the prevention of measles, hepatitis A, hepatitis B, tetanus, varicella, rabies, and vaccinia. Although their use in the treatment of bacterial infection has largely been supplanted by antibiotics, antibodies remain a critical component of the treatment of diptheria, tetanus, and botulism. High-dose intravenous immunoglobulin can be used to treat certain viral infections in immunocompromised patients (e.g., cytomegalovirus, parvovirus B19, and enterovirus infections). Antibodies may also be of value in toxic shock syndrome, Ebola virus, and refractory staphylococcal infections. Palivizumab, the first monoclonal antibody licensed (in 1998) for an infectious disease, can prevent respiratory syncytial virus infection in high-risk infants. The development and use of additional monoclonal antibodies to key epitopes of microbial pathogens may further define protective humoral responses and lead to new approaches for the prevention and treatment of infectious diseases.

show abstract

Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation [letter]

Cited by 7 publications

References 0 publications

In vitroantiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases*

In vitroantiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases*

Therapeutic Use of Immunoglobulins

Passive Immunity in Prevention and Treatment of Infectious Diseases

Contact Info

Product

Resources

About